

	I	II	III	IV
RNAiMAX Merck	0.78% \pm 0.23%	1.19% \pm 0.52%	5.11% \pm 1.87%	12.24% \pm 4.05%
RNAiMAX Abgent	0.20% \pm 0.24%	0.19% \pm 0.17%	0.20% \pm 0.18%	0.33% \pm 0.29%
	V	VI	VII	VIII
RNAiMAX Merck	14.97% \pm 1.52%	16.87% \pm 0.48%	36.96% \pm 6.05%	39.89% \pm 3.10%
RNAiMAX Abgent	0.15% \pm 0.27%	0.25% \pm 0.32%	0.25% \pm 0.28%	0.24% \pm 0.09%
	I	II	III	IV
Lipof. 3000 Merck	0.51% \pm 0.16%	0.62% \pm 0.08%	0.26% \pm 0.10%	0.17% \pm 0.08%
Lipof. 3000 Abgent	0.31% \pm 0.14%	0.24% \pm 0.08%	0.33% \pm 0.21%	0.39% \pm 0.08%
	V	VI	VII	VIII
Lipof. 3000 Merck	0.56% \pm 0.14%	0.22% \pm 0.01%	0.46% \pm 0.11%	0.98% \pm 0.57%
Lipof. 3000 Abgent	0.19% \pm 0.19%	0.32% \pm 0.17%	0.29% \pm 0.25%	0.38% \pm 0.33%

Supplemental Table S2 Phenotype incidences obtained after solid-phase transfection of two KIF11 antibodies (Merck and Abgent) in HeLa cells, complexed with Lipofectamine®RNAiMAX or Lipofectamine®3000. The transfections were performed in 384-well plates. Cells were fixed 24 hours post transfection. Phenotype analysis and quantification was performed as described in Methods.